Probiotic Claims Disputes in Animal Health
- Dr. Nihan
- Apr 3
- 4 min read
When CFU Counts, Strain IDs, and Shelf-Life Promises End Up in Court
The Probiotic Market Is Booming and So Are the Disputes
The global animal probiotics market is growing at double-digit rates. Pet owners are spending more on gut health, immunity, and microbiome-based products than ever before. And where money flows, litigation follows.
The disputes I’m seeing fall into three categories: products that don’t contain what the label says they contain (CFU discrepancies), products that contain the wrong organisms entirely (strain identification errors), and products that lose viability before the stated expiration date (shelf-life misrepresentation). Each of these creates a different legal theory, and each requires different scientific expertise to evaluate.
CFU Count Discrepancies: The Most Common Probiotic Claim Failure
A probiotic label that says “10 billion CFU per serving” is making a quantitative promise. If independent testing shows the product contains 2 billion CFU at the time of purchase, the company has a problem.
But here’s the part that makes these cases complicated: probiotics are living organisms. They die over time. A responsible manufacturer formulates with an “overage” adding more CFU at the time of manufacture than the label claims, to account for die-off during storage. The question in litigation becomes: did the manufacturer use adequate overage? Did they conduct proper stability testing? And does the label represent CFU at manufacture or at end of shelf life?
These distinctions matter enormously in court. An expert who has actually formulated probiotic products and conducted stability testing can explain them. An expert who has only read the literature cannot.
Strain Identification Errors (When the Label Says One Thing and the Product Contains Another)
Not all probiotics are created equal. A product labeled as containing Lactobacillus acidophilus that actually contains Lactobacillus rhamnosus is not just a labeling error — it’s a fundamentally different organism with different clinical properties.
Strain-level identification requires molecular methods (16S rRNA sequencing, whole genome sequencing). Traditional plating methods can identify genus and species but often miss strain-level differences. When a company hasn’t invested in proper strain verification, the door opens for disputes over product identity, efficacy claims, and consumer fraud.
I’ve seen this in the real world... companies selling products based on strain identity claims they never actually verified at the molecular level.
Shelf-Life Misrepresentation & Stability Testing Failures
A probiotic product with a “Best By” date is implicitly promising the consumer that the product remains viable through that date. But viability depends on storage conditions, formulation, excipients, packaging, and the inherent stability characteristics of the specific strains used.
Proper stability testing follows accelerated and real-time protocols, evaluating CFU counts at defined intervals under controlled temperature and humidity conditions. Companies that shortcut this process -estimating shelf life based on limited data or using stability data from a different formulation- expose themselves to claims of misrepresentation.
In litigation, the expert’s role is to evaluate whether the stability testing protocol was scientifically sound, whether the data supports the claimed shelf life, and whether the consumer received a product that met the labeled specification at the time of purchase.
The Problem: Microbiome/Probiotic Claims (Gut Health, Immunity, and Substantiation)
Beyond CFU and strain issues, there’s a broader category of disputes around efficacy claims. When a pet probiotic says “supports digestive health” or “strengthens immune function,” what evidence substantiates that claim?
For animal health products, the regulatory framework is strict: the FDA can classify any product making such claims as an unapproved animal drug. But even in the commercial context (B2B disputes between suppliers and brands, or IP disputes between competitors), the question of claims substantiation comes up constantly.
Does the company have clinical data supporting the claim? Was the data generated using the specific strain and formulation in the finished product? Or was it borrowed from published literature on a different strain? These are the questions that end up in depositions.
Why This Space Needs a Specialized Expert Witness
Probiotic disputes sit at the intersection of microbiology, food science, regulatory law, and manufacturing engineering. A clinical microbiologist may understand the organisms but not the manufacturing process. A food scientist may understand formulation but not regulatory classification. A regulatory attorney may understand the legal framework but can’t evaluate the science.
The expert who can do all of this, evaluate the strain biology, assess the manufacturing and stability data, interpret the regulatory landscape, and communicate it clearly in court is rare. That’s where I come in.
Expert Witness for Probiotic, Microbiome, and Biotics Product Disputes
Dr. Nihan Marun is a veterinary microbiologist (DVM, PhD Microbiology) who has commercialized 20+ probiotic and microbial products globally. She has hands-on experience in strain selection, CFU verification, formulation development, GMP manufacturing, stability testing, and regulatory submissions for probiotic products across FDA-CVM, USDA, AAFCO, EU, and APAC frameworks.
She developed The Responsible Biotics Framework™ - a proprietary methodology for evaluating microbiome-based products from science to market.
Available for both plaintiff and defense. Nationwide and international.
